RxDoctor Payments Data

Alice Cavanagh, MD

Cardiovascular Disease · Garden City, NYNPI 1699731851

Payments from drug & device makers

$3,879in general payments, 2019–2025

Across 93 payments — averaging $41.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Amgen$630
  • AstraZeneca$378
  • Sanofi-aventis U.S. LLC$251
  • Boehringer Ingelheim$239
  • Pfizer$222
  • plus $808 from 5 others

What the payments were for

  • Speaking & faculty fees$1253%
  • Food & beverage$3,74797%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,879 in reported general payments places this provider in the 65th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$318,436
Medicare patients
905
Services billed
3,784

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban77$101,658
EliquisApixaban72$95,414
OzempicSemaglutide24$25,042
Repatha SureclickEvolocumab15$23,348
MultaqDronedarone Hcl13$22,918
TrintellixVortioxetine Hydrobromide12$15,759
EntrestoSacubitril/Valsartan11$8,354
SynthroidLevothyroxine Sodium82$5,718
Breo ElliptaFluticasone/Vilanterol11$5,587
Metoprolol Succinate274$4,463
Atorvastatin Calcium353$3,597
Rosuvastatin Calcium238$3,325
Diltiazem 24hr Er (Cd)Diltiazem Hcl47$3,308
Ezetimibe-SimvastatinEzetimibe/Simvastatin11$2,335
Amlodipine Besylate271$2,176

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$1,352$101,65877 claims
PfizerEliquis$222$95,41472 claims
Novo NordiskOzempic$125$25,04224 claims
Sanofi-aventis U.S. LLCMultaq$251$22,91813 claims
NovartisEntresto$150$8,35411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Garden City

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →